A Study of LY3537031 in Overweight, Obese, and Healthy Participants

Description

This is a 3-part study that includes a Part A, Part B, and Part C. Part A will study the safety and tolerability of the study drug known as LY3537031 in participants who are overweight and obese. Part B and Part C will study the safety and tolerability of LY3537031 in healthy participants. Part C will contain only Japanese and Chinese healthy participants. Blood tests will be performed to check how much LY3537031 gets into the bloodstream and how long it takes the body to eliminate it. Body weight will be measured. The study will last approximately 48 weeks excluding a screening period.

Conditions

Healthy, Obesity

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a 3-part study that includes a Part A, Part B, and Part C. Part A will study the safety and tolerability of the study drug known as LY3537031 in participants who are overweight and obese. Part B and Part C will study the safety and tolerability of LY3537031 in healthy participants. Part C will contain only Japanese and Chinese healthy participants. Blood tests will be performed to check how much LY3537031 gets into the bloodstream and how long it takes the body to eliminate it. Body weight will be measured. The study will last approximately 48 weeks excluding a screening period.

A Multiple-Ascending Dose Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of LY3537031 in Overweight and Obese Participants and Healthy Volunteers

A Study of LY3537031 in Overweight, Obese, and Healthy Participants

Condition
Healthy
Intervention / Treatment

-

Contacts and Locations

Los Alamitos

Collaborative Neuroscience Research, LLC, Los Alamitos, California, United States, 90720

Daytona Beach

Fortrea Clinical Research Unit, Daytona Beach, Florida, United States, 32117

Miami

Clinical Pharmacology of Miami, Miami, Florida, United States, 33172

Springfield

QPS, Springfield, Missouri, United States, 65802

Dallas

Fortrea Clinical Research Unit, Dallas, Texas, United States, 75247

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Have a BMI within the range of:
  • * Part A: 27.0 to 45.0 kilogram per square meter (kg/m²)
  • * Part B: 22.0 to 26.9 kg/m²
  • * Parts B and C: Weigh 60 kg (80 lbs) or more at screening
  • * Have no significant (not more than 5%) self-reported weight gain or loss in the past 3 months prior to screening
  • * Have a thyroid stimulating hormone (TSH) value within normal local laboratory ranges.
  • * Have undergone any form of bariatric surgery
  • * Participants who are lactating
  • * Have taken medications that promote weight loss within 90 days before screening
  • * Have a serum calcitonin level (at screening) of greater than or equal to 35 nanograms per liter (ng/L) (35 picograms per milliliter (pg/mL))

Ages Eligible for Study

22 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Eli Lilly and Company,

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), STUDY_DIRECTOR, Eli Lilly and Company

Study Record Dates

2026-07